BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12712409)

  • 1. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
    Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
    J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
    Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
    Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion of human prostate tumorigenic growth by azatyrosine.
    Benoit RM; Eiseman J; Jacobs SC; Kyprianou N
    Urology; 1995 Sep; 46(3):370-7. PubMed ID: 7660512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
    Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
    Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
    Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW
    Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
    Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
    Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
    Zhang AL; Russell PJ; Knittel T; Milross C
    Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
    Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of expression of Na+,K+-ATPase in androgen-dependent and androgen-independent prostate cancer.
    Blok LJ; Chang GT; Steenbeek-Slotboom M; van Weerden WM; Swarts HG; De Pont JJ; van Steenbrugge GJ; Brinkmann AO
    Br J Cancer; 1999 Sep; 81(1):28-36. PubMed ID: 10487609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of differentially expressed genes in LNCaP prostate cancer progression model.
    Xie BX; Zhang H; Wang J; Pang B; Wu RQ; Qian XL; Yu L; Li SH; Shi QG; Huang CF; Zhou JG
    J Androl; 2011; 32(2):170-82. PubMed ID: 20864652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.